Clinical Trials Available at Panama City Oncology

Lung

RTOG 0117; Phase I/II dose intensification study using 2 dimensional conformal radiation therapy and concurrent chemoradiation for patients with inoperable, non-small cell lung cancer.

RTOG 0212;  A phase II/III randomized trial of two dose schedules for delivering prophylactic cranial irradiation for patients with limited disease small cell lung cancer.

RTOG 0214; A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer.

RTOG 0320; A phase III trial comparing whole brain radiation and stereotactic radiosurgery alone vs. Temozolomide or Gefitinib in patients with non-small cell lung cancer and 1-3 brain metastasis (Gefitinib changed to Erlotinib 5-05)

Breast

RTOG 0413/NSABP B-39; a ranomized Phase III study of conventional whole breast irradiation (WBI) versus partial breast (PBI) for women with stage 0, I, or II breast cancer.

Gynecological

RTOG 0418; A phase II study of IMRT to the Pelvis +/- Chemotherapy for post op patient with Endometrial or Cervical Cancer.  Endometrial arm closed.

Genito-urinary

RTOG 0521; A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT vs. AS and 3DCRT/IMRT followed by chemotherapy with Docetaxel and Prednisone for localized, high-risk prostate cancer.

RTOG 0126; A phase III randomized study of high dose 3DCRT/IMRT versus standard dose 3D-CRT/IMRT in patients treated for localized prostate cancer.

RTOG 0415; A phase III randomized study of hypofractionated 3DCRT/IMRT versus conventionally fractionated 3DCRT/IMRT in patients with favorable risk prostate cancer. 

Head and Neck

RTOG 0522; A randomized phase III trial of concurrent accelerated radiation and Cisplatin vs. concurrent accelerated radiation, Cisplatin and Cetuximab (C225) [followed by surgery for selected patients] for stage II and IV head and neck carcinomas.   

Brain

RTOG 0525;  A phase II trial comparing conventional adjuvant Temozolomide with dose intensive Temozolomide in patients with newly diagnosed Glioblastoma.

Gastrointestinal

RTOG 0529;  A phase II evaluation of dose painted IMRT in combination with 5-Fluorouracil and Mitomycin C for reduction of acute morbidity in carcinoma of the anal canal.